SNS Insider projects 14.64% CAGR through 2035, citing broader ATTR-CM diagnosis, uptake of gene-silencing therapies and TTR stabilizers, recent FDA approvals including vutrisiran and AMVUTTRA, and faster growth in Asia Pacific.
The transthyretin amyloidosis treatment market was valued at USD 8.95 billion in 2025 and is projected to reach USD 35.10 billion by 2035, expanding at a CAGR of 14.64% during 2026–2035, according to SNS Insider. The report says growth is being driven by higher diagnosis rates for ATTR-CM, wider use of gene-silencing therapies and TTR stabilizers, supportive regulatory approvals, advances in nuclear cardiac imaging such as technetium pyrophosphate scans, and rising investment in rare disease therapeutics. Targeted therapy led with 87.14% of 2025 revenue, ATTR-PN accounted for 78.25% by type, wild-type amyloidosis held a 54.08% disease share, and hospital pharmacies represented 52.31% of revenue, while pipeline therapy, ATTR-CM, hereditary transthyretin amyloidosis, online pharmacies, and Asia Pacific are projected to grow fastest.